• Clinical science
  • Clinician

Pulmonary embolism


Pulmonary embolism (PE) is the obstruction of one or more pulmonary arteries by solid, liquid, or gaseous masses. In most cases, the embolism is caused by blood thrombi, which arise from the deep vein system in the legs or pelvis (deep vein thrombosis) and embolize to the lungs via the inferior vena cava. Risk factors include immobility, inherited hypercoagulability disorders, pregnancy, and recent surgery. The clinical presentation is variable and, depending on the extent of vessel obstruction, can range from asymptomatic to obstructive shock. Symptoms are often nonspecific, including chest pain, coughing, dyspnea, and tachycardia. The diagnosis of PE is based primarily on the clinical findings and is confirmed by the detection of an embolism in CT pulmonary angiography (CTPA). Arterial blood gas analysis typically shows evidence of respiratory alkalosis with low partial oxygen pressure, low partial carbon dioxide pressure, and elevated pH. Another commonly performed test is the measurement of D-dimer levels, which can rule out PE if negative. Anticoagulation with heparin is initiated to prevent further thromboembolisms as well as to promote the gradual dissolution of the embolism and the underlying thrombosis. In massive PE with obstructive shock, the thrombus is resolved with thrombolytic agents or thrombectomy.


Epidemiological data refers to the US, unless otherwise specified.


PE is FATAL: PE caused by Fat, Air, Thrombus, Amniotic fluid, and Less common, i.e., bacterial, tumor, and cement.


Clinical features

Consider PE as a differential diagnosis in recurring or progressive dyspnea of uncertain etiology.

Pretest probability of pulmonary embolism

There are several externally validated decision tools that can be used to assess the pretest probability of PE. These include the original Wells score and modified Wells score, revised Geneva score, and pulmonary embolism rule-out criteria (PERC). None of these scoring systems have been found to have greater levels of accuracy than the others. [6][7]

Wells criteria for pulmonary embolism [8]

The Wells score is a diagnostic algorithm for assessing the probability of PE and has been validated in inpatient and outpatient settings. Note that a different version is used for determining the probability of DVT. (See “Wells criteria for DVT.”)

Wells criteria for PE [9][10]
Criteria Points
Clinical symptoms of DVT 3
PE more likely than other diagnoses 3
Previous PE/DVT 1.5
Tachycardia (Heart rate > 100/min) 1.5
Surgery or immobilization in the past 4 weeks 1.5


Malignancy 1
Original Wells score (clinical probability) [9]

Modified Wells score (clinical probability) [10]

  • Total score ≤ 4: PE unlikely (8%)
  • Total score > 4: PE likely (34%)

Revised Geneva score [11]

The revised Geneva score utilizes objective clinical variables. It has been externally validated and was initially studied in emergency department outpatients.

Revised Geneva score [9]
Criteria Points
Age > 65 years 1
Prior history of DVT or PE 3
Recent surgery or fracture of the lower limbs 2
Personal history of cancer 2
Unilateral lower limb pain 3
Hemoptysis 2
Heart rate 75–94/min 3
Heart rate ≥ 95/min 5
Pain on palpation of lower limb and unilateral edema 4

Clinical pretest probability

Pulmonary embolism rule-out criteria (PERC) [7][12][13]

PERC is only used for patients who have a low pretest probability of PE based on either their Wells score for pulmonary embolism or revised Geneva score.

Pulmonary embolism rule-out criteria (PERC)
Criteria Points
Age > 50 years 1
Heart rate > 100/min 1
Oxygen saturation < 95% 1
Hemoptysis 1
Estrogen use 1
Prior history of DVT or PE 1
Recent surgery or trauma in the past 4 weeks 1
Unilateral lower limb edema 1

Clinical pretest probability

  • Total score 0: pretest probability < 1%; no further testing needed
  • Total score ≥ 1: PE is not ruled out; further testing needed

PERC should only be used in patients with a low pretest probability of PE.


Diagnostic approach [4][7]

  1. Assess for hemodynamic stability.
    • Stable patients: systolic BP > 90 mm Hg
    • Unstable patients: systolic BP < 90 mm Hg for > 15 minutes, evidence of shock, or BP drop > 40 mm Hg for > 15 minutes
  2. Assess the pretest probability of PE.
  3. Obtain other laboratory studies or imaging as needed.

Laboratory studies [7]

D-dimer levels [7]

  • Indication: pretest probability of PE is either low and does not meet PERC OR is intermediate
  • Findings
    • Normal levels: < 500 ng/mL
    • If ≥ 500 ng/mL: Further testing is required (see below).
    • If the patient is > 50 years of age, adjust for age: age x 10 ng/mL = cut off value in ng/mL
  • Interpretation

Normal D-dimer values can usually rule out PE or DVT in patients with unremarkable history and physical examination! A positive D-dimer is nonspecific, since it may be elevated in any situation where there is increased fibrinolysis.

Additional testing


CT pulmonary angiography (CTPA)

Ventilation/perfusion scintigraphy (V/Q scan) [19]

Echocardiography [21]

Lower extremity venous ultrasound [19]

Chest x-ray [19]

Pulmonary angiography [19]

  • Definition: an invasive radiological procedure performed with contrast dye to visualize the pulmonary vasculature
  • Procedure: Right heart catheterization insertion of a catheter into a pulmonary artery→ angiography following administration of contrast agent
  • Indications
    • Planning of concomitant endovascular treatment [19]
    • Suspicion for PE is high despite negative findings. [18]
  • Findings: intraluminal filling defects in pulmonary arteries

Magnetic resonance pulmonary angiography [24]

  • Indications: when standard imaging (CTPA or V/Q scan) cannot be performed
  • Findings: similar to CTPA [19]

Additional diagnostics

Electrocardiography (ECG) [25]

Identifying the underlying cause

  • Evaluation for thrombophilia [31]
    • Indicated in younger patients with any of the following
      • No or weak risk factors
      • Family history
      • Recurrence of venous thrombosis
    • Timing: after the completion of therapy
    • See “Hypercoagulable states.”
  • Evaluation for malignancies: age-appropriate screening studies



  1. Stabilize the patient and provide supportive care.
    • Pulseless patient with suspected PE: Start ACLS and consider administration of thrombolytics (e.g., tPA ). [32][33].
  2. Assess bleeding risk (see risk factors for bleeding in patients with VTE).
  3. Consider empiric parenteral anticoagulation while awaiting a definitive diagnosis.
  4. Risk stratify the patient based on prognostic models (see risk stratification of pulmonary embolism).
  5. Consult pulmonary embolism response team (PERT), if available. [34]
  6. Initiate therapy based on risk stratification and bleeding risk.

Supportive care

Hypervolemia can be harmful if right ventricle strain is present.

Assessment of bleeding risk

There are currently no scoring systems with sufficient prediction outcomes for the bleeding risk from anticoagulant therapy in patients with PE. The HAS-BLED score is sometimes used but it was designed and validated for anticoagulant therapy in patients with atrial fibrillation. See risk factors for bleeding in patients with VTE. [36]

Empiric parenteral anticoagulation for pulmonary embolism

  • Indications: consider starting empiric anticoagulation in patients awaiting a definitive diagnosis, depending on the risk of bleeding, the pretest probability of PE, and the expected timing of the diagnostic study [33][35]
    • Low probability of PE and diagnostic study is expected to be delayed > 24 hours [33]
    • Intermediate probability of PE and diagnostic study is expected to be delayed > 4 hours [33]
    • High probability of PE
  • Absolute contraindication: high bleeding risk
  • Choice of medication [33][35]

An absolute contraindication for empiric anticoagulation is a high risk of bleeding (e.g., recent surgery, hemorrhagic stroke, active bleeding).

Risk stratification of pulmonary embolism

Risk categories based on the risk of adverse outcomes [38][39]

Pulmonary Embolism Severity Index (PESI) and simplified PESI (sPESI) [40][41]

The Pulmonary Embolism Severity Index stratifies the risk of mortality or adverse outcomes and is used to assist in decisions on inpatient vs. outpatient management.

Criteria Points
PESI [40] sPESI [41]
Age 1 per year 1 if > 80 years
History of cancer 30 1
Systolic blood pressure < 100 mm Hg 30 1
Heart rate ≥ 110/min 20 1
O2 saturation on room air < 90% 20 1
Heart failure 10 1
Chronic lung disease 10
Altered mental status 60 Not considered
Temperature < 96.8°F (< 37°C) 20
Respiratory rate ≥ 30/min 20

Male: 10

Female: 0

PESI interpretation (30-day mortality rate, inpatient mortality) [40]

  • < 66 points: class I, very low risk (0–1.6%, ≤ 1.1%)
  • 66–85 points: class II, low risk (1.7–3.5%, ≤ 1.9%)
  • 86–105 points: class III, intermediate risk (3.2–7.1%, ≤ 4.7%)
  • 106–125 points: class IV, high risk (4.0–11.4%, ≤ 7.0%)
  • > 125 points: class V, very high risk (10.0–23.9%, ≤ 17.2%)

sPESI interpretation (30-day mortality) [41]

  • 0 points: low risk (1%)
  • ≥ 1 point: high risk (10.9%)

Treatment of massive pulmonary embolism

Initiate directed therapy based on bleeding risk and the presence of any contraindications to thrombolytic therapy in massive pulmonary embolism.

Thrombolytic therapy in pulmonary embolism

Systemic thrombolysis [37]

Catheter-directed thrombolysis [37]

Contraindications to thrombolysis

Contraindications to thrombolytic therapy in massive pulmonary embolism [37]
Absolute contraindications
Relative contraindications

Embolectomy in pulmonary embolism [33]

  • Indication: : treatment of last resort when thrombolysis is contraindicated or unsuccessful
  • Procedure: surgical or catheter-based thrombus removal

Treatment of nonmassive pulmonary embolism and submassive pulmonary embolism

Initiate directed therapy based on the bleeding risk on anticoagulation for VTE.

Anticoagulation for pulmonary embolism [33][37][39][44]

Specific populations [37]

Acute management checklist

Initial management

  • Hemodynamic support in patients with hypotension
  • Supplemental oxygen as needed
  • Analgesics
  • Consult Pulmonary Embolism Response Team (PERT). [34]

Nonmassive and submassive pulmonary embolism

  • Assess bleeding risk and consider empiric parenteral anticoagulation while awaiting definitive diagnosis.
  • If bleeding risk is low to moderate, start anticoagulation (see anticoagulation for pulmonary embolism).
  • If bleeding risk is high, consider IVC filter placement.
  • Consider continuous pulse oximetry and/or continuous telemetry.
  • In select patients with very low-risk PE (e.g., sPESI = 0): Consider outpatient therapy.
  • In patients with subsegmental PE with low risk of recurrent VTE: Consider clinical surveillance only.

Massive pulmonary embolism

Pulseless patient with suspected PE

  • Start ACLS.
  • Consider administration of reduced dose of tPA.


We list the most important complications. The selection is not exhaustive.

Differential diagnoses


  • Purpose: distinguishing cause of embolism (See “Etiology” above.)
  • Histological findings [45]
    • Lines of Zahn: alternating layers of platelets mixed with fibrin (light pink layers) and red blood cells (dark red layers)
    • Only appear premortally (help distinguish a premortal thrombus from a postmortem one)

Related One-Minute Telegram

Interested in the newest medical research, distilled down to just one minute? Sign up for the One-Minute Telegram in “Tips and links” below.

  • 1. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous Thromboembolism. Am J Prev Med. 2010; 38(4): pp. S495–S501. doi: 10.1016/j.amepre.2009.12.017.
  • 2. Calkovska A, Mokra D, Calkovsky V. Lung surfactant alterations in pulmonary thromboembolism. Eur J Med Res. 2009; 14(Suppl 4): p. 38. doi: 10.1186/2047-783x-14-s4-38.
  • 3. Lyhne MD, Kline JA, Nielsen-Kudsk JE, Andersen A. Pulmonary vasodilation in acute pulmonary embolism – a systematic review. Pulmonary Circulation. 2020; 10(1): p. 204589401989977. doi: 10.1177/2045894019899775.
  • 4. Agnelli G, Becattini C. Acute Pulmonary Embolism. N Engl J Med. 2010; 363(3): pp. 266–274. doi: 10.1056/nejmra0907731.
  • 5. Hagio K, Sugano N, Takashina M, Nishii T, Yoshikawa H, Ochi T. Embolic events during total hip arthroplasty: An echocardiographic study. J Arthroplasty. 2003; 18(2): pp. 186–192. doi: 10.1054/arth.2003.50027.
  • 6. Douma RA, Mos ICM, Erkens PMG, et al. Performance of 4 Clinical Decision Rules in the Diagnostic Management of Acute Pulmonary Embolism. Ann Intern Med. 2011; 154(11): pp. 709–18. doi: 10.7326/0003-4819-154-11-201106070-00002.
  • 7. Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015; 163(9): pp. 701–11. doi: 10.7326/m14-1772.
  • 8. Wells PS. Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism. Ann Intern Med. 1998; 129(12): pp. 997–1005. doi: 10.7326/0003-4819-129-12-199812150-00002.
  • 9. Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost. 2010. doi: 10.1111/j.1538-7836.2010.03801.x.
  • 10. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000; 83(3): pp. 416–20. pmid: 10744147.
  • 11. Le Gal G, Righini M, Roy P-M, et al. Prediction of Pulmonary Embolism in the Emergency Department: The Revised Geneva Score. Ann Intern Med. 2006; 144(3): pp. 165–171. doi: 10.7326/0003-4819-144-3-200602070-00004.
  • 12. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008; 6(5): pp. 772–780. doi: 10.1111/j.1538-7836.2008.02944.x.
  • 13. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004; 2(8): pp. 1247–1255. doi: 10.1111/j.1538-7836.2004.00790.x.
  • 14. Rodger MA, Carrier M, Jones GN, et al. Diagnostic Value of Arterial Blood Gas Measurement in Suspected Pulmonary Embolism. Am J Respir Crit Care Med. 2000; 162(6): pp. 2105–2108. doi: 10.1164/ajrccm.162.6.2004204.
  • 15. Stein PD, Goldhaber SZ, Henry JW, Miller AC. Arterial Blood Gas Analysis in the Assessment of Suspected Acute Pulmonary Embolism. Chest. 1996; 109(1): pp. 78–81. doi: 10.1378/chest.109.1.78.
  • 16. Müller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem. 2002; 48(4): pp. 673–5. pmid: 11901075.
  • 17. Klok FA, Mos ICM, Huisman MV. Brain-Type Natriuretic Peptide Levels in the Prediction of Adverse Outcome in Patients with Pulmonary Embolism. Am J Respir Crit Care Med. 2008; 178(4): pp. 425–430. doi: 10.1164/rccm.200803-459oc.
  • 18. Wilbur J, Shian B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am Fam Physician. 2012; 86(10): pp. 913–9. pmid: 23157144.
  • 19. Moore AJE, Wachsmann J, Chamarthy MR, Panjikaran L, Tanabe Y, Rajiah P. Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther. 2018; 8(3): pp. 225–243. doi: 10.21037/cdt.2017.12.01.
  • 20. Sostman HD, Stein PD, Gottschalk A, Matta F, Hull R, Goodman L. Acute Pulmonary Embolism: Sensitivity and Specificity of Ventilation-Perfusion Scintigraphy in PIOPED II Study. Radiology. 2008; 246(3): pp. 941–946. doi: 10.1148/radiol.2463070270.
  • 21. Fields JM, Davis J, Girson L, et al. Transthoracic Echocardiography for Diagnosing Pulmonary Embolism: A Systematic Review and Meta-Analysis. J Am Soc Echocardiogr. 2017; 30(7): pp. 714–723.e4. doi: 10.1016/j.echo.2017.03.004.
  • 22. Meyerovitz MF, Mannting F, Polak JF, Goldhaber SZ. Frequency of Pulmonary Embolism in Patients with Low-Probability Lung Scan and Negative Lower Extremity Venous Ultrasound. Chest. 1999; 115(4): pp. 980–982. doi: 10.1378/chest.115.4.980.
  • 23. Van Rossum AB, van Houwelingen HC, Kieft GJ, Pattynama PM. Prevalence of deep vein thrombosis in suspected and proven pulmonary embolism: a meta-analysis. Br J Radiol. 1998; 71(852): pp. 1260–1265. doi: 10.1259/bjr.71.852.10318998.
  • 24. Stein PD. Gadolinium-Enhanced Magnetic Resonance Angiography for Pulmonary Embolism. Ann Intern Med. 2010; 152(7): pp. 434–43. doi: 10.7326/0003-4819-152-7-201004060-00008.
  • 25. Shopp JD, Stewart LK, Emmett TW, Kline JA. Findings From 12-lead Electrocardiography That Predict Circulatory Shock From Pulmonary Embolism: Systematic Review and Meta-analysis. Acad Emerg Med. 2015; 22(10): pp. 1127–1137. doi: 10.1111/acem.12769.
  • 26. Co I, Eilbert W, Chiganos T. New Electrocardiographic Changes in Patients Diagnosed with Pulmonary Embolism. J Emerg Med. 2017; 52(3): pp. 280–285. doi: 10.1016/j.jemermed.2016.09.009.
  • 27. Geibel A, Zehender M, Kasper W, et al. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. European Respiratory Journal. 2005; 25(5): pp. 843–848. doi: 10.1183/09031936.05.00119704.
  • 28. Alreshq R, Hsu G, Torosoff M. Acute Pulmonary Embolism Presenting with Symptomatic Bradycardia: A Case Report and Review of the Literature. Am J Case Rep. 2019; 20: pp. 748–752. doi: 10.12659/ajcr.915609.
  • 29. Daniel KR, Courtney DM, Kline JA. Assessment of Cardiac Stress From Massive Pulmonary Embolism With 12-Lead ECG. Chest. 2001; 120(2): pp. 474–481. doi: 10.1378/chest.120.2.474.
  • 30. Mohsen A, El-Kersh K. Variable ECG findings associated with pulmonary embolism. Case Reports. 2013; 2013(feb28 1): pp. bcr2013008697–bcr2013008697. doi: 10.1136/bcr-2013-008697.
  • 31. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med. 2017; 377(12): pp. 1177–1187. doi: 10.1056/nejmra1700365.
  • 32. Sharifi M, Berger J, Beeston P, Bay C, Vajo Z, Javadpoor S. Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the “PEAPETT” study). Am J Emerg Med. 2016; 34(10): pp. 1963–1967. doi: 10.1016/j.ajem.2016.06.094.
  • 33. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): pp. e419S–e496S. doi: 10.1378/chest.11-2301.
  • 34. Chaudhury P, Gadre S, Schneider E, et al. Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes. Am J Cardiol. 2019; 124(9): pp. 1465–1469. doi: 10.1016/j.amjcard.2019.07.043.
  • 35. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019; 54(3): p. 1901647. doi: 10.1183/13993003.01647-2019.
  • 36. Klok FA, Niemann C, Dellas C, et al. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis. 2016; 41(2): pp. 312–20. doi: 10.1007/s11239-015-1239-x.
  • 37. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016; 149(2): pp. 315–352. doi: 10.1016/j.chest.2015.11.026.
  • 38. Jaff MR, McMurtry MS, Archer SL, et al. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2011; 123(16): pp. 1788–1830. doi: 10.1161/cir.0b013e318214914f.
  • 39. Konstantinides SV, Barco S, Lankeit M, Meyer G. Management of Pulmonary Embolism. J Am Coll Cardiol. 2016; 67(8): pp. 976–990. doi: 10.1016/j.jacc.2015.11.061.
  • 40. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and Validation of a Prognostic Model for Pulmonary Embolism. Am J Respir Crit Care Med. 2005; 172(8): pp. 1041–1046. doi: 10.1164/rccm.200506-862oc.
  • 41. Jiménez D, Aujesky D, Moores L, et al. Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. Arch Intern Med. 2010; 170(15): pp. 1383–9. doi: 10.1001/archinternmed.2010.199.
  • 42. Condliffe R, Elliot CA, Hughes RJ, et al. Management dilemmas in acute pulmonary embolism. Thorax. 2013; 69(2): pp. 174–180. doi: 10.1136/thoraxjnl-2013-204667.
  • 43. Daley MJ, Murthy MS, Peterson EJ. Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. Ther Adv Drug Saf. 2015; 6(2): pp. 57–66. doi: 10.1177/2042098615572333.
  • 44. Wilbur J, Shian B. Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy. Am Fam Physician. 2017; 95(5): pp. 295–302. pmid: 28290648.
  • 45. Fineschi V, Turillazzi E, Neri M, Pomara C, Riezzo I. Histological age determination of venous thrombosis: A neglected forensic task in fatal pulmonary thrombo-embolism. Forensic Sci Int. 2009; 186(1-3): pp. 22–28. doi: 10.1016/j.forsciint.2009.01.006.
  • Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008; 100(1): pp. 26–31. doi: 10.1160/TH08-03-0193.
  • Becattini C, Agnelli G, Lankeit M, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal. 2016; 48(3): pp. 780–786. doi: 10.1183/13993003.00024-2016.
last updated 11/18/2020
{{uncollapseSections(['efaxOP', 'JjcsYc0', 'Tfa6lP', 'SfaylP', 'hfacNP', '_dc5sY0', 'ifaJNP', 'PfaWmP', '-dcDsY0', '4fa3mP', 'zdcrsY0', '0VceGY0', 'bJ1Hs30'])}}